Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.41), $0.03 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.09 million versus the consensus estimate of $8.21 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.